High cyclooxygenase-2 expression in stage IB cervical cancer with lymph node metastasis or parametrial invasion

被引:154
作者
Ryu, HS [1 ]
Chang, KH [1 ]
Yang, HW [1 ]
Kim, MS [1 ]
Kwon, HC [1 ]
Oh, KS [1 ]
机构
[1] Ajou Univ, Sch Med, Dept Obstet & Gynecol, Suwon 442721, South Korea
关键词
cervical cancer; tumor invasion; apoptosis; cyclooxygenase (COX)-2;
D O I
10.1006/gyno.1999.5690
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. The enzymes cyclooxygenase (COX)-1 and -2 are necessary for the synthesis of prostaglandins. COX-2 is usually absent in normal cells and is upregulated and expressed as a product of the "immediate early" gene during inflammatory processes. In previous studies, the expression of COX-2 has been shown to be induced by proinflammatory cytokines, and suggestions have been made that overexpression of COX-2 suppresses apoptosis and is directly related to tumor growth. We have attempted to determine a relationship between tumor invasion and metastasis of uterine cervical cancer and COX and apoptosis by comparing the protein expression of apoptosis, COX-1, and COX-2 in tumor tissues. Methods. The subjects were 36 patients who were FIGO stage TS uterine cervical cancer patients who underwent surgery at Ajou University Hospital. There were 12 cases with lymph node or parametrial involvement. All tissues were subjected to immunohistochemical staining for COX-I, -2, and TUNEL method for apoptosis detection, and the following results were obtained. Results. Tumor tissues confirmed by cytokeratin were separated into tumor surface, tumor stroma, and invasion site portions, in which decreased apoptosis was observed in the invasion sites. COX-2 expression was observed in all tumor tissues and was especially strong in the tumor invasion site. Therefore, it is suggested that COX-2 expression may suppress cell apoptosis at the tumor invasion site. When COX-2 expression was investigated according to the groups with regard to the presence of lymph node or parametrial involvement, there was a statistically significant (Mann-Whitney U test) COX-2 expression difference in the tumor invasion site (P value = 0.040) and the tumor stroma (P value = 0.028). Conclusions. In surgically treated stage IB cervical cancer patients, COX-2 was significantly expressed when lymph node or parametrial involvement was present. These results suggest that the expression of COX-2 in stage IB cervical cancer may downregulate apoptosic processes and thus enhance tumor invasion and metastasis. a (C)2000 Academic Press.
引用
收藏
页码:320 / 325
页数:6
相关论文
共 26 条
[1]   Regulation of COX-2 gene expression in rat uterus in vivo and in vitro [J].
Arslan, A ;
Zingg, HH .
PROSTAGLANDINS, 1996, 52 (06) :463-481
[2]   Cellular mechanisms involved during oxytocin-induced prostaglandin F-2 alpha production in endometrial epithelial cells in vitro: Role of cyclooxygenase-2 [J].
Asselin, E ;
Drolet, P ;
Fortier, MA .
ENDOCRINOLOGY, 1997, 138 (11) :4798-4805
[3]   PROGNOSTIC FACTORS IN STAGE I CARCINOMA OF THE CERVIX [J].
BOYCE, J ;
FRUCHTER, RG ;
NICASTRI, AD ;
AMBIAVAGAR, PC ;
REINIS, MS ;
NELSON, JH .
GYNECOLOGIC ONCOLOGY, 1981, 12 (02) :154-165
[4]   PROGNOSTIC FACTORS AND OPERATIVE TREATMENT OF STAGE-IB TO STAGE-IIB CERVICAL-CANCER [J].
BURGHARDT, E ;
PICKEL, H ;
HAAS, J ;
LAHOUSEN, M .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1987, 156 (04) :988-996
[5]   OBJECTIVE RESULTS OF THE OPERATIVE TREATMENT OF CERVICAL-CANCER [J].
BURGHARDT, E ;
PICKEL, H ;
HAAS, J ;
LAHOUSEN, M .
BAILLIERES CLINICAL OBSTETRICS AND GYNAECOLOGY, 1988, 2 (04) :987-995
[6]   PARAMETRIAL INVOLVEMENT AND THERAPEUTIC PROGRAMMING IN STAGE-IB CERVICAL-CANCER [J].
CARENZA, L ;
VILLANI, C .
BAILLIERES CLINICAL OBSTETRICS AND GYNAECOLOGY, 1988, 2 (04) :889-902
[7]  
Crofford LJ, 1997, J RHEUMATOL, V24, P15
[8]   YES, BUT DO THEY STILL GET HEADACHES [J].
DEWITT, D ;
SMITH, WL .
CELL, 1995, 83 (03) :345-348
[9]   Differential expression of cyclooxygenase-1 and -2 proteins in rat uterus and cervix during the estrous cycle, pregnancy, labor and in myometrial cells [J].
Dong, YL ;
Gangula, PRR ;
Fang, L ;
Yallampalli, C .
PROSTAGLANDINS, 1996, 52 (01) :13-34
[10]  
HU Z, 1992, J PHARMACOL EXP THER, V262, P334